Home › presentation
 

Keywords :   


Tag: presentation

Blue Ribbon Commission Presentation

2014-10-02 19:11:41| PortlandOnline

PDF Document, 2,703kbCategory: First Budget Advisory Committee Meeting

Tags: blue presentation commission ribbon

 

2014 Utility Rate Review Presentation

2014-10-02 19:10:10| PortlandOnline

PDF Document, 8,617kbCategory: First Budget Advisory Committee Meeting

Tags: review rate presentation utility

 
 

FME conference presentation highlights open source

2014-10-01 17:41:00| Oil IT Journal - www.oilit.com

Devon Energy uses Safe Software's FME, OpenGeo and Apache Solr to GIS-enable SCADA.

Tags: open source open source conference

 

Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014

2014-09-29 11:00:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. KEYTRUDA monotherapy achieved 24 percent overall response rate in patients with PD-L1 positive, advanced bladder (urothelial) cancer Planned Phase 3 study in advanced bladder cancer to be initiated by the end of 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data on the investigational use of KEYTRUDA (pembrolizumab) the companys anti-PD-1 therapy in PD-L1 positive, advanced urothelial cancer (also known as bladder cancer). Language: English Contact: MerckMedia:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with data advanced early

 

MSD Announces First Presentation of Data on the Investigational Use of Pembrolizumab in Patients with Advanced Gastric Cancer at ESMO 2014

2014-09-28 09:15:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. Pembrolizumab monotherapy achieved 31 percent overall response rate in patients with PD-L1 positive, advanced gastric cancer Phase 2 study to be initiated in first quarter of 2015 (KEYNOTE-059) WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--MSD, known as Merck in the United States and Canada, today announced the first presentation of data on the investigational use of pembrolizumab the companys anti-PD-1 therapy in PD-L1 positive, advanced gastric cancer. The early findings presented showed an overall response rate (confirmed and unconfirmed) of 31 percent with pembrolizumab as monotherapy, as measured by investigator assessed, RECIST v1.1 (n= 12/39: 95% CI, 17-47). Language: English Contact: For MSDMedia:Ian McConnell, 973-901-5722orClaire Mulhearn, 908-423-7425orInvestors:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with data advanced presentation

 

Sites : [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] next »